ESPEROVAX Trademark

Trademark Overview

On Wednesday, December 20, 2023, a trademark application was filed for ESPEROVAX with the United States Patent and Trademark Office. The USPTO has given the ESPEROVAX trademark a serial number of 98324183. The federal status of this trademark filing is PUBLICATION/ISSUE REVIEW COMPLETE as of Tuesday, November 5, 2024. This trademark is owned by Esperovax, Inc.. The ESPEROVAX trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

Vaccines; Oral vaccines; Modified cells for medical or clinical use; yeast-based pharmaceuticals for prevention or treatment of infectious diseases; Oral vaccine preparations; Pharmaceutical products for the treatment of infectious diseases; Recombinant yeast-based pharmaceutical products for prevention or treatment of infectious diseases; Yeast-based oral vaccines; Pharmaceutical preparations, namely, a drug delivery system for oral administration of vaccines comprising yeast-based oral vaccines; Pharmaceutical products, namely, yeast-based oral vaccines; Biological and pharmaceutical preparations, namely, recombinant yeast for prevention or treatment of infectious diseases

Medical research in the field of vaccines and medicines; Research and development of vaccines and medicines; Research and development in the pharmaceutical and biotechnology fields; Scientific research in the field of vaccines and medicines; Pharmaceutical research and development; Research and development in the field of immunology; Research and development in the field of microorganisms, namely, research and development related to yeast; Research and development in the field of therapeutics; Development of pharmaceutical preparations and medicines; Scientific study and research in the field of medicine; Scientific study and research in the field of healthcare products; Medical and scientific research; Research and development of pharmaceutical and therapeutic preparations; Pharmaceutical, biologic, and vaccine research and development
esperovax

General Information

Serial Number98324183
Word MarkESPEROVAX
Filing DateWednesday, December 20, 2023
Status681 - PUBLICATION/ISSUE REVIEW COMPLETE
Status DateTuesday, November 5, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 26, 2024

Trademark Statements

Goods and ServicesVaccines; Oral vaccines; Modified cells for medical or clinical use; yeast-based pharmaceuticals for prevention or treatment of infectious diseases; Oral vaccine preparations; Pharmaceutical products for the treatment of infectious diseases; Recombinant yeast-based pharmaceutical products for prevention or treatment of infectious diseases; Yeast-based oral vaccines; Pharmaceutical preparations, namely, a drug delivery system for oral administration of vaccines comprising yeast-based oral vaccines; Pharmaceutical products, namely, yeast-based oral vaccines; Biological and pharmaceutical preparations, namely, recombinant yeast for prevention or treatment of infectious diseases
Goods and ServicesMedical research in the field of vaccines and medicines; Research and development of vaccines and medicines; Research and development in the pharmaceutical and biotechnology fields; Scientific research in the field of vaccines and medicines; Pharmaceutical research and development; Research and development in the field of immunology; Research and development in the field of microorganisms, namely, research and development related to yeast; Research and development in the field of therapeutics; Development of pharmaceutical preparations and medicines; Scientific study and research in the field of medicine; Scientific study and research in the field of healthcare products; Medical and scientific research; Research and development of pharmaceutical and therapeutic preparations; Pharmaceutical, biologic, and vaccine research and development

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, December 20, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE
International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateWednesday, December 20, 2023
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameEsperovax, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressPlymouth, MI 48170

Trademark Events

Event DateEvent Description
Wednesday, December 20, 2023NEW APPLICATION ENTERED
Monday, April 1, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, July 22, 2024ASSIGNED TO EXAMINER
Tuesday, July 23, 2024NON-FINAL ACTION WRITTEN
Tuesday, July 23, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, July 23, 2024NON-FINAL ACTION E-MAILED
Wednesday, October 23, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, October 23, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, October 23, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, October 30, 2024EXAMINERS AMENDMENT -WRITTEN
Wednesday, October 30, 2024EXAMINERS AMENDMENT E-MAILED
Wednesday, October 30, 2024EXAMINER'S AMENDMENT ENTERED
Wednesday, October 30, 2024NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Wednesday, October 30, 2024APPROVED FOR PUB - PRINCIPAL REGISTER

Related Keywords

esperovax research pharmaceutical development vaccines yeast field oral preparations based products